| Serial Number | 79425878 |
| Word Mark | NANOSYRINX |
| Filing Date | Tuesday, March 25, 2025 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Tuesday, March 17, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Scientific and technological services, namely, research and design in the fields of biology, medicine, pharmaceuticals, drug delivery, biotechnology, gene editing, drug discovery, and vaccines; research services, namely, scientific research; biotechnological research services; drug discovery services; medical and scientific research, namely, conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research in the field of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; services for assessing the efficacy of pharmaceuticals in the nature of pharmaceutical product development and evaluation; research and development in the field of drug delivery agents; pharmaceutical research and development in the field of gene editing; information, advisory and consultancy services relating to all of the aforesaid |
| Goods and Services | Pharmaceutical and veterinary pharmaceutical preparations, namely, drug delivery systems comprising extracellular contractile injection systems for the targeted intracellular delivery of a wide variety of therapeutic biological molecules, drugs and therapeutic substances; pharmaceutical preparations and substances, being a wide variety of therapeutic biological molecules, drugs and therapeutic substances for the targeted intracellular delivery by drug delivery systems comprising extracellular contractile injection systems; pharmaceutical preparations for intracellular delivery of drugs being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; veterinary preparations for intracellular delivery of drugs being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens, for delivering biological molecules, drugs and therapeutics to target cells; pharmaceutical preparations for intracellular delivery of antibodies being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical antibodies; veterinary preparations for intracellular delivery of antibodies being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical antibodies; pharmaceutical preparations for intracellular delivery of enzymes being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical enzymes; veterinary preparations for intracellular delivery of enzymes being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical enzymes; pharmaceutical preparations for intracellular delivery of antibody fragments being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical antibody fragments; veterinary preparations for intracellular delivery of antibody fragments being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceutical antibody fragments; pharmaceutical preparations for gene editing for the treatment of genetic diseases, neurological diseases, cancer, congenital diseases, autoimmune diseases, inflammatory diseases, degenerative diseases, and endocrine diseases; veterinary preparations for gene editing for the treatment of genetic diseases, neurological diseases, cancer, congenital diseases, autoimmune diseases, inflammatory diseases, degenerative diseases, and endocrine diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing RNA; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing RNA; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on non-viral delivery technology being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of non-viral pharmaceuticals; veterinary preparations for intracellular delivery of therapeutic substances focused on non-viral delivery technology being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of non-viral pharmaceuticals; pharmaceutical preparations for intracellular delivery of nucleic acids being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of nucleic acid pharmaceuticals; veterinary preparations for intracellular delivery of nucleic acids being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of nucleic acid pharmaceuticals; pharmaceutical preparations for intracellular delivery of proteins being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing proteins; veterinary preparations for intracellular delivery of proteins being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing proteins; pharmaceutical preparations for intracellular delivery of peptides being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing peptides; veterinary preparations for intracellular delivery of peptides being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing peptides; pharmaceutical preparations for intracellular delivery of small molecules being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing small molecules; veterinary preparations for intracellular delivery of small molecules being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing small molecules; pharmaceutical substances for intracellular delivery of drugs being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical substances for gene editing for the treatment of genetic diseases, neurological diseases, cancer, congenital diseases, autoimmune diseases, inflammatory diseases, degenerative diseases, and endocrine diseases; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing RNA; pharmaceutical substances for intracellular delivery of therapeutic substances focused on non-viral delivery technology being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of non-viral pharmaceuticals; pharmaceutical substances for intracellular delivery of nucleic acids being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of nucleic acid pharmaceuticals; pharmaceutical substances for intracellular delivery of proteins being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing proteins; pharmaceutical preparations for intracellular delivery of peptides being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing peptides; pharmaceutical substances for intracellular delivery of peptides being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing proteins; pharmaceutical substances for intracellular delivery of small molecules being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing small molecules; drug delivery agents consisting of compounds or biological molecules that facilitate delivery of a wide range of pharmaceuticals; biological pharmaceuticals, namely, biologics in the nature of pharmaceutical preparations for the treatment of genetic diseases, neurological diseases, cancer, congenital diseases, autoimmune diseases, inflammatory diseases, degenerative diseases, and endocrine diseases; drug delivery agents for delivering pharmaceuticals to target cells being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals to target cells; agents for delivering proteins to target cells being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals to target cells; agents for delivering peptides to target cells being drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals containing peptides to target cells; bacterial preparations for pharmaceutical purposes; bacterial preparations for medical purposes; bacterial and viral preparations and cultures and preparations of micro-organisms, all for medical and veterinary use; media for the storage of micro-organisms and bacteria being cell culture media for medical purposes, bacteriological cultures for medical and veterinary purposes; nutritive substances for micro-organisms for medical purposes and veterinary purposes; nutrients for microbial cultures being micro-nutrient preparations for cultivating drug delivery agents consisting of genetically-encoded protein complexes and protein assemblies capable of binding to cell-surface antigens that facilitate delivery of a wide range of pharmaceuticals; culture media for cultivating bacteriological cultures, bacteria and living microorganisms for medical and veterinary purposes; bacterial cultures being bacterial preparations for medical and veterinary use; cultures of microorganisms for medical and veterinary use; bacterial and bacteriological preparations for medical or veterinary use; diagnostic preparations and substances, namely, diagnostic preparations for medical and veterinary purposes; diagnostic preparations and substances being diagnostic preparations for medical and veterinary purposes, all for in vivo use; cell preparations being cells for medical and veterinary purposes, nutrients for cell cultures being nutrient preparations for cultivating drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; cell growth media for growing cells for medical use; living cells for medical use |
| Goods and Services | Cultures and preparations of micro-organisms other than for medical and veterinary use; chemicals for use in science and industry; chemicals and chemical reagents for use in the preparation of biological delivery systems, namely for the maintenance of biological cells, for the preparation of cell culture media, for the modification of proteins, peptides, nucleic acids and biological molecules, to assist the binding of biological cargo to biological carriers, and for measuring the effect of biological delivery systems, all for in vitro use; chemical reagents for identification of microorganisms, other than for medical or veterinary use; cell culture media except for medical and veterinary purposes, namely, for research use; chemicals for analysis in laboratories being chemicals for use in industry and science; media for cell culture for use in research in the biotechnological industry; cultures of cell media for research use; nutritive agents for processing living cells other than for medical use, namely, nutritive substances for microorganism cultures, for the targeted intracellular delivery of biological molecules; nutrition agents for processing living cells other than for medical use, namely, nutrition substances for microorganism cultures, for the targeted intracellular delivery of biological molecules; biological preparations for use in cell cultures other than for medical or veterinary use; preparations of living microorganisms, other than for medical or veterinary use; chemicals and polymers, all being industrial chemicals for use in the pharmaceutical industry; proteins in raw material form for scientific research and development; peptide preparations used as biological cargo for the targeted intracellular delivery of biological molecules, for facilitating the targeted intracellular delivery of biological molecules, for targeting cells for the delivery of biological molecules, for controlling the delivery of biological molecules to target cells, for tracking and measuring the delivery of biological molecules to target cells, other than for medical or veterinary purposes; proteins in raw material form for use in science, for scientific and medical research; laboratory reagents for scientific use; laboratory reagents for scientific use, namely, for intracellular delivery of peptides, proteins, enzymes, gene editing enzymes, antibodies or antibody fragments |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 12, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | NANOSYRINX LTD |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Thursday, June 12, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, June 13, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 13, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, August 22, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, September 9, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 10, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, October 27, 2025 | LETTER OF PROTEST EVIDENCE FORWARDED |
| Monday, October 27, 2025 | REFUSAL PROCESSED BY MPU |
| Monday, October 27, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Saturday, November 15, 2025 | REFUSAL PROCESSED BY IB |
| Wednesday, November 26, 2025 | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN |
| Tuesday, March 17, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, March 17, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, March 17, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |